Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
10-Yr Benchmark Govt Yields - U.S. vs Other Nations

10-Yr Benchmark Govt Yields - U.S. vs Other Nations

Dow JonesDow Jones2026/10/08 12:10

Current Spread in Yield Basis Points U.S. 5.330 % Australia 5.403 % 7.3 Belgium 4.395 % -93.5 Canada 3.948 % -138.2 Denmark 3.313 % -201.7 France 4.903 % -42.7 Germany 3.524 % -180.6 Italy 4.635 % -69.5 Japan 3.086 % -224.4 Netherlands 3.636 % -169.4 Spain 4.148 % -118.2 Sweden 3.226 % -210.4 U.K. 5.477 % 14.7 Source: Tullett Prebon via FactSet (END) Dow Jones Newswires October 08, 2026 08:10 ET (12:10 GMT)

Current Spread in Yield Basis Points

U.S. 5.330 % Australia 5.403 % 7.3 Belgium 4.395 % -93.5 Canada 3.948 % -138.2 Denmark 3.313 % -201.7 France 4.903 % -42.7 Germany 3.524 % -180.6 Italy 4.635 % -69.5 Japan 3.086 % -224.4 Netherlands 3.636 % -169.4 Spain 4.148 % -118.2 Sweden 3.226 % -210.4 U.K. 5.477 % 14.7

Source: Tullett Prebon via FactSet

(END) Dow Jones Newswires

October 08, 2026 08:10 ET (12:10 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss